APO Research
Talk to an analyst

APO RESEARCH · REPORT

ICAD (Intracranial Atherosclerotic Disease) Pathology

Intracranial atherosclerotic disease is the progressive narrowing of the cerebral arteries within the skull (intracranial). The arteries that supply oxygen-enriched blood to the brain are the carotid arteries and the vertebral arteries. The circle of Willis is the area at the base of the brain that joins these arteries. Stenosis (narrowing) of the artery walls in intracranial atherosclerotic disease (ICAD) develops similarly to atherosclerosis of the heart: from the buildup of plaque, also known as an atherosclerotic lesion. The product in this report is Stent and PTA balloon for Treatment of ICAD.

Explore the product
View pricing & licenses

Product & engineering

Understand the product.

Intracranial atherosclerotic disease is the progressive narrowing of the cerebral arteries within the skull (intracranial). The arteries that supply oxygen-enriched blood to the brain are the carotid arteries and the vertebral arteries. The circle of Willis is the area at the base of the brain that joins these arteries. Stenosis (narrowing) of the artery walls in intracranial atherosclerotic disease (ICAD) develops similarly to atherosclerosis of the heart: from the buildup of plaque, also known as an atherosclerotic lesion. The product in this report is Stent and PTA balloon for Treatment of ICAD.

Selected research

Market Outlook & Growth Opportunities

Global ICAD (Intracranial Atherosclerotic Disease) Pathology Market Outlook and Growth Opportunities 2026

9 January 2026194 pages

Choose your research edition.

Industry ResearchICAD (Intracranial Atherosclerotic Disease) Pathology Industry Research Report 2026118 pages · $2,950 USDIndustry Growth & TrendsGlobal ICAD (Intracranial Atherosclerotic Disease) Pathology Industry Growth and Trends Forecast to 203299 pages · $3,450 USDMarket StructureGlobal ICAD (Intracranial Atherosclerotic Disease) Pathology Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032189 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal ICAD (Intracranial Atherosclerotic Disease) Pathology Market Outlook and Growth Opportunities 2026194 pages · $4,250 USDMarket Analysis & ForecastGlobal ICAD (Intracranial Atherosclerotic Disease) Pathology Market Analysis and Forecast 2026-2032193 pages · $4,950 USD

Market perspective

Intracranial atherosclerotic disease is the progressive narrowing of the cerebral arteries within the skull (intracranial). The arteries that supply oxygen-enriched blood to the brain are the carotid arteries and the vertebral arteries. The circle of Willis is the area at the base of the brain that joins these arteries. Stenosis (narrowing) of the artery walls in intracranial atherosclerotic disease (ICAD) develops similarly to atherosclerosis of the heart: from the buildup of plaque, also known as an atherosclerotic lesion. The product in this report is Stent and PTA balloon for Treatment of ICAD.

Global ICAD (Intracranial Atherosclerotic Disease) Pathology key players include Stryker, Balt, TERUMO, MicroPort, Acandis, etc. Global top five manufacturers hold a share about 90%. Asia-Pacific is the largest market, with a share about 45%, followed by North America, with a share about 25 percent. In terms of product, Stent is the largest segment, with a share about 80%. And in terms of application, the largest application is Hospital, followed by Clinic, etc.

This report provides an overview of the global ICAD (Intracranial Atherosclerotic Disease) Pathology market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

Read the full market overview

The study covers key producers of ICAD (Intracranial Atherosclerotic Disease) Pathology and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents ICAD (Intracranial Atherosclerotic Disease) Pathology sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the ICAD (Intracranial Atherosclerotic Disease) Pathology market size, projected growth trends, production technologies, key applications, and end-use industries.

ICAD (Intracranial Atherosclerotic Disease) Pathology Segment by Company

Stryker

Balt

TERUMO

MicroPort

Acandis

ICAD (Intracranial Atherosclerotic Disease) Pathology Segment by Type

Stent

PTA Balloon

ICAD (Intracranial Atherosclerotic Disease) Pathology Segment by Application

Hospital

Clinic

Other

ICAD (Intracranial Atherosclerotic Disease) Pathology Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global ICAD (Intracranial Atherosclerotic Disease) Pathology status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions ICAD (Intracranial Atherosclerotic Disease) Pathology market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify ICAD (Intracranial Atherosclerotic Disease) Pathology significant trends, drivers, influence factors in global and regions.

6. To analyze ICAD (Intracranial Atherosclerotic Disease) Pathology competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global ICAD (Intracranial Atherosclerotic Disease) Pathology market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of ICAD (Intracranial Atherosclerotic Disease) Pathology and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of ICAD (Intracranial Atherosclerotic Disease) Pathology.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the ICAD (Intracranial Atherosclerotic Disease) Pathology market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global ICAD (Intracranial Atherosclerotic Disease) Pathology industry.

Chapter 3: Detailed analysis of ICAD (Intracranial Atherosclerotic Disease) Pathology manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of ICAD (Intracranial Atherosclerotic Disease) Pathology in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of ICAD (Intracranial Atherosclerotic Disease) Pathology in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. ICAD (Intracranial Atherosclerotic Disease) Pathology Industry Trends Table 2. ICAD (Intracranial Atherosclerotic Disease) Pathology Industry Drivers Table 3. ICAD (Intracranial Atherosclerotic Disease) Pathology Industry Opportunities and Challenges Table 4. ICAD (Intracranial Atherosclerotic Disease) Pathology Industry Restraints Table 5. Global ICAD (Intracranial Atherosclerotic Disease) Pathology Revenue by Company (US$ Million) & (2021-2026) Table 6. Global ICAD (Intracranial Atherosclerotic Disease) Pathology Revenue Share by Company (2021-2026) Table 7. Global ICAD (Intracranial Atherosclerotic Disease) Pathology Sales Volume by Company (Units) & (2021-2026) Table 8. Global ICAD (Intracranial Atherosclerotic Disease) Pathology Sales Volume Share by Company (2021-2026) Table 9. Global ICAD (Intracranial Atherosclerotic Disease) Pathology Average Price (USD/Unit) of Company (2021-2026) Table 10. Global ICAD (Intracranial Atherosclerotic Disease) Pathology Company Ranking, (2024-2026) & (USD Million) Table 11. Global ICAD (Intracranial Atherosclerotic Disease) Pathology Key Company Manufacturing Base & Headquarters Table 12. Global ICAD (Intracranial Atherosclerotic Disease) Pathology Company, Product Type & Application Table 13. Global ICAD (Intracranial Atherosclerotic Disease) Pathology Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global ICAD (Intracranial Atherosclerotic Disease) Pathology by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Stent Table 18. Significant Companies of PTA Balloon Table 19. Global ICAD (Intracranial Atherosclerotic Disease) Pathology Sales Volume by Type 2021 VS 2025 VS 2032 (Units) Table 20. Global ICAD (Intracranial Atherosclerotic Disease) Pathology Sales Volume by Type (2021-2026) & (Units) Table 21. Global ICAD (Intracranial Atherosclerotic Disease) Pathology Sales Volume by Type (2027-2032) & (Units) Table 22. Global ICAD (Intracranial Atherosclerotic Disease) Pathology Sales Volume Share by Type (2021-2026) Table 23. Global ICAD (Intracranial Atherosclerotic Disease) Pathology Sales Volume Share by Type (2027-2032) Table 24. Global ICAD (Intracranial Atherosclerotic Disease) Pathology Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global ICAD (Intracranial Atherosclerotic Disease) Pathology Sales Value by Type (2021-2026) & (US$ Million) Table 26. Global ICAD (Intracranial Atherosclerotic Disease) Pathology Sales Value by Type (2027-2032) & (US$ Million) Table 27. Global ICAD (Intracranial Atherosclerotic Disease) Pathology Sales Value Share by Type (2021-2026) Table 28. Global ICAD (Intracranial Atherosclerotic Disease) Pathology Sales Value Share by Type (2027-2032) Table 29. Significant Companies of Hospital Table 30. Significant Companies of Clinic Table 31. Significant Companies of Other Table 32. Global ICAD (Intracranial Atherosclerotic Disease) Pathology Sales Volume by Application 2021 VS 2025 VS 2032 (Units) Table 33. Global ICAD (Intracranial Atherosclerotic Disease) Pathology Sales Volume by Application (2021-2026) & (Units) Table 34. Global ICAD (Intracranial Atherosclerotic Disease) Pathology Sales Volume by Application (2027-2032) & (Units) Table 35. Global ICAD (Intracranial Atherosclerotic Disease) Pathology Sales Volume Share by Application (2021-2026) Table 36. Global ICAD (Intracranial Atherosclerotic Disease) Pathology Sales Volume Share by Application (2027-2032) Table 37. Global ICAD (Intracranial Atherosclerotic Disease) Pathology Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 38. Global ICAD (Intracranial Atherosclerotic Disease) Pathology Sales Value by Application (2021-2026) & (US$ Million) Table 39. Global ICAD (Intracranial Atherosclerotic Disease) Pathology Sales Value by Application (2027-2032) & (US$ Million) Table 40. Global ICAD (Intracranial Atherosclerotic Disease) Pathology Sales Value Share by Application (2021-2026) Table 41. Global ICAD (Intracranial Atherosclerotic Disease) Pathology Sales Value Share by Application (2027-2032) Table 42. Global ICAD (Intracranial Atherosclerotic Disease) Pathology Sales by Region: 2021 VS 2025 VS 2032 (Units) Table 43. Global ICAD (Intracranial Atherosclerotic Disease) Pathology Sales by Region (2021-2026) & (Units) Table 44. Global ICAD (Intracranial Atherosclerotic Disease) Pathology Sales Market Share by Region (2021-2026) Table 45. Global ICAD (Intracranial Atherosclerotic Disease) Pathology Sales by Region (2027-2032) & (Units) Table 46. Global ICAD (Intracranial Atherosclerotic Disease) Pathology Sales Market Share by Region (2027-2032) Table 47. Global ICAD (Intracranial Atherosclerotic Disease) Pathology Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 48. Global ICAD (Intracranial Atherosclerotic Disease) Pathology Sales Value by Region (2021-2026) & (US$ Million) Table 49. Global ICAD (Intracranial Atherosclerotic Disease) Pathology Sales Value Share by Region (2021-2026) Table 50. Global ICAD (Intracranial Atherosclerotic Disease) Pathology Sales Value by Region (2027-2032) & (US$ Million) Table 51. Global ICAD (Intracranial Atherosclerotic Disease) Pathology Sales Value Share by Region (2027-2032) Table 52. Global ICAD (Intracranial Atherosclerotic Disease) Pathology Market Average Price (USD/Unit) by Region (2021-2026) Table 53. Global ICAD (Intracranial Atherosclerotic Disease) Pathology Market Average Price (USD/Unit) by Region (2027-2032) Table 54. Global ICAD (Intracranial Atherosclerotic Disease) Pathology Sales by Country: 2021 VS 2025 VS 2032 (Units) Table 55. Global ICAD (Intracranial Atherosclerotic Disease) Pathology Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 56. Global ICAD (Intracranial Atherosclerotic Disease) Pathology Sales by Country (2021-2026) & (Units) Table 57. Global ICAD (Intracranial Atherosclerotic Disease) Pathology Sales Market Share by Country (2021-2026) Table 58. Global ICAD (Intracranial Atherosclerotic Disease) Pathology Sales by Country (2027-2032) & (Units) Table 59. Global ICAD (Intracranial Atherosclerotic Disease) Pathology Sales Market Share by Country (2027-2032) Table 60. Global ICAD (Intracranial Atherosclerotic Disease) Pathology Sales Value by Country (2021-2026) & (US$ Million) Table 61. Global ICAD (Intracranial Atherosclerotic Disease) Pathology Sales Value Market Share by Country (2021-2026) Table 62. Global ICAD (Intracranial Atherosclerotic Disease) Pathology Sales Value by Country (2027-2032) & (US$ Million) Table 63. Global ICAD (Intracranial Atherosclerotic Disease) Pathology Sales Value Market Share by Country (2027-2032) Table 64. Stryker Company Information Table 65. Stryker Business Overview Table 66. Stryker ICAD (Intracranial Atherosclerotic Disease) Pathology Sales (Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 67. Stryker ICAD (Intracranial Atherosclerotic Disease) Pathology Product Portfolio Table 68. Stryker Recent Development Table 69. Balt Company Information Table 70. Balt Business Overview Table 71. Balt ICAD (Intracranial Atherosclerotic Disease) Pathology Sales (Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 72. Balt ICAD (Intracranial Atherosclerotic Disease) Pathology Product Portfolio Table 73. Balt Recent Development Table 74. TERUMO Company Information Table 75. TERUMO Business Overview Table 76. TERUMO ICAD (Intracranial Atherosclerotic Disease) Pathology Sales (Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 77. TERUMO ICAD (Intracranial Atherosclerotic Disease) Pathology Product Portfolio Table 78. TERUMO Recent Development Table 79. MicroPort Company Information Table 80. MicroPort Business Overview Table 81. MicroPort ICAD (Intracranial Atherosclerotic Disease) Pathology Sales (Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 82. MicroPort ICAD (Intracranial Atherosclerotic Disease) Pathology Product Portfolio Table 83. MicroPort Recent Development Table 84. Acandis Company Information Table 85. Acandis Business Overview Table 86. Acandis ICAD (Intracranial Atherosclerotic Disease) Pathology Sales (Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 87. Acandis ICAD (Intracranial Atherosclerotic Disease) Pathology Product Portfolio Table 88. Acandis Recent Development Table 89. Key Raw Materials Table 90. Raw Materials Key Suppliers Table 91. ICAD (Intracranial Atherosclerotic Disease) Pathology Distributors List Table 92. ICAD (Intracranial Atherosclerotic Disease) Pathology Customers List Table 93. Research Programs/Design for This Report Table 94. Authors List of This Report Table 95. Secondary Sources Table 96. Primary Sources List of Figures Figure 1. ICAD (Intracranial Atherosclerotic Disease) Pathology Product Image Figure 2. Global ICAD (Intracranial Atherosclerotic Disease) Pathology Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global ICAD (Intracranial Atherosclerotic Disease) Pathology Sales Value (2021-2032) & (US$ Million) Figure 4. Global ICAD (Intracranial Atherosclerotic Disease) Pathology Sales (2021-2032) & (Units) Figure 5. Global ICAD (Intracranial Atherosclerotic Disease) Pathology Sales Average Price (USD/Unit) & (2021-2032) Figure 6. Global ICAD (Intracranial Atherosclerotic Disease) Pathology Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Stent Image Figure 10. PTA Balloon Image Figure 11. Global ICAD (Intracranial Atherosclerotic Disease) Pathology Sales Volume by Type (2021 VS 2025 VS 2032) & (Units) Figure 12. Global ICAD (Intracranial Atherosclerotic Disease) Pathology Sales Volume Share 2021 VS 2025 VS 2032 Figure 13. Global ICAD (Intracranial Atherosclerotic Disease) Pathology Sales Volume Share by Type (2021-2032) Figure 14. Global ICAD (Intracranial Atherosclerotic Disease) Pathology Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 15. Global ICAD (Intracranial Atherosclerotic Disease) Pathology Sales Value Share 2021 VS 2025 VS 2032 Figure 16. Global ICAD (Intracranial Atherosclerotic Disease) Pathology Sales Value Share by Type (2021-2032) Figure 17. Hospital Image Figure 18. Clinic Image Figure 19. Other Image Figure 20. Global ICAD (Intracranial Atherosclerotic Disease) Pathology Sales Volume by Application (2021 VS 2025 VS 2032) & (Units) Figure 21. Global ICAD (Intracranial Atherosclerotic Disease) Pathology Sales Volume Share 2021 VS 2025 VS 2032 Figure 22. Global ICAD (Intracranial Atherosclerotic Disease) Pathology Sales Volume Share by Application (2021-2032) Figure 23. Global ICAD (Intracranial Atherosclerotic Disease) Pathology Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 24. Global ICAD (Intracranial Atherosclerotic Disease) Pathology Sales Value Share 2021 VS 2025 VS 2032 Figure 25. Global ICAD (Intracranial Atherosclerotic Disease) Pathology Sales Value Share by Application (2021-2032) Figure 26. Global ICAD (Intracranial Atherosclerotic Disease) Pathology Sales by Region: 2021 VS 2025 VS 2032 (Units) Figure 27. Global ICAD (Intracranial Atherosclerotic Disease) Pathology Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 28. Global ICAD (Intracranial Atherosclerotic Disease) Pathology Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 29. Global ICAD (Intracranial Atherosclerotic Disease) Pathology Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 30. North America ICAD (Intracranial Atherosclerotic Disease) Pathology Sales Value (2021-2032) & (US$ Million) Figure 31. North America ICAD (Intracranial Atherosclerotic Disease) Pathology Sales Value Share by Country (%), 2025 VS 2032 Figure 32. Europe ICAD (Intracranial Atherosclerotic Disease) Pathology Sales Value (2021-2032) & (US$ Million) Figure 33. Europe ICAD (Intracranial Atherosclerotic Disease) Pathology Sales Value Share by Country (%), 2025 VS 2032 Figure 34. Asia-Pacific ICAD (Intracranial Atherosclerotic Disease) Pathology Sales Value (2021-2032) & (US$ Million) Figure 35. Asia-Pacific ICAD (Intracranial Atherosclerotic Disease) Pathology Sales Value Share by Country (%), 2025 VS 2032 Figure 36. South America ICAD (Intracranial Atherosclerotic Disease) Pathology Sales Value (2021-2032) & (US$ Million) Figure 37. South America ICAD (Intracranial Atherosclerotic Disease) Pathology Sales Value Share by Country (%), 2025 VS 2032 Figure 38. Middle East & Africa ICAD (Intracranial Atherosclerotic Disease) Pathology Sales Value (2021-2032) & (US$ Million) Figure 39. Middle East & Africa ICAD (Intracranial Atherosclerotic Disease) Pathology Sales Value Share by Country (%), 2025 VS 2032 Figure 40. USA ICAD (Intracranial Atherosclerotic Disease) Pathology Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 41. USA ICAD (Intracranial Atherosclerotic Disease) Pathology Sales Value Share by Type, 2025 VS 2032 & (%) Figure 42. USA ICAD (Intracranial Atherosclerotic Disease) Pathology Sales Value Share by Application, 2025 VS 2032 & (%) Figure 43. Canada ICAD (Intracranial Atherosclerotic Disease) Pathology Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. Canada ICAD (Intracranial Atherosclerotic Disease) Pathology Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. Canada ICAD (Intracranial Atherosclerotic Disease) Pathology Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. Mexico ICAD (Intracranial Atherosclerotic Disease) Pathology Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. Mexico ICAD (Intracranial Atherosclerotic Disease) Pathology Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. Mexico ICAD (Intracranial Atherosclerotic Disease) Pathology Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. Germany ICAD (Intracranial Atherosclerotic Disease) Pathology Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. Germany ICAD (Intracranial Atherosclerotic Disease) Pathology Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. Germany ICAD (Intracranial Atherosclerotic Disease) Pathology Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. France ICAD (Intracranial Atherosclerotic Disease) Pathology Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. France ICAD (Intracranial Atherosclerotic Disease) Pathology Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. France ICAD (Intracranial Atherosclerotic Disease) Pathology Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. U.K. ICAD (Intracranial Atherosclerotic Disease) Pathology Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. U.K. ICAD (Intracranial Atherosclerotic Disease) Pathology Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. U.K. ICAD (Intracranial Atherosclerotic Disease) Pathology Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. Italy ICAD (Intracranial Atherosclerotic Disease) Pathology Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. Italy ICAD (Intracranial Atherosclerotic Disease) Pathology Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. Italy ICAD (Intracranial Atherosclerotic Disease) Pathology Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Spain ICAD (Intracranial Atherosclerotic Disease) Pathology Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Spain ICAD (Intracranial Atherosclerotic Disease) Pathology Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Spain ICAD (Intracranial Atherosclerotic Disease) Pathology Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. Russia ICAD (Intracranial Atherosclerotic Disease) Pathology Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. Russia ICAD (Intracranial Atherosclerotic Disease) Pathology Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. Russia ICAD (Intracranial Atherosclerotic Disease) Pathology Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. Netherlands ICAD (Intracranial Atherosclerotic Disease) Pathology Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. Netherlands ICAD (Intracranial Atherosclerotic Disease) Pathology Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. Netherlands ICAD (Intracranial Atherosclerotic Disease) Pathology Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. Nordic Countries ICAD (Intracranial Atherosclerotic Disease) Pathology Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. Nordic Countries ICAD (Intracranial Atherosclerotic Disease) Pathology Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. Nordic Countries ICAD (Intracranial Atherosclerotic Disease) Pathology Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. China ICAD (Intracranial Atherosclerotic Disease) Pathology Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. China ICAD (Intracranial Atherosclerotic Disease) Pathology Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. China ICAD (Intracranial Atherosclerotic Disease) Pathology Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. Japan ICAD (Intracranial Atherosclerotic Disease) Pathology Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. Japan ICAD (Intracranial Atherosclerotic Disease) Pathology Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. Japan ICAD (Intracranial Atherosclerotic Disease) Pathology Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. South Korea ICAD (Intracranial Atherosclerotic Disease) Pathology Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. South Korea ICAD (Intracranial Atherosclerotic Disease) Pathology Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. South Korea ICAD (Intracranial Atherosclerotic Disease) Pathology Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. India ICAD (Intracranial Atherosclerotic Disease) Pathology Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. India ICAD (Intracranial Atherosclerotic Disease) Pathology Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. India ICAD (Intracranial Atherosclerotic Disease) Pathology Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. Australia ICAD (Intracranial Atherosclerotic Disease) Pathology Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. Australia ICAD (Intracranial Atherosclerotic Disease) Pathology Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. Australia ICAD (Intracranial Atherosclerotic Disease) Pathology Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Southeast Asia ICAD (Intracranial Atherosclerotic Disease) Pathology Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Southeast Asia ICAD (Intracranial Atherosclerotic Disease) Pathology Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Southeast Asia ICAD (Intracranial Atherosclerotic Disease) Pathology Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Brazil ICAD (Intracranial Atherosclerotic Disease) Pathology Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Brazil ICAD (Intracranial Atherosclerotic Disease) Pathology Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Brazil ICAD (Intracranial Atherosclerotic Disease) Pathology Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Argentina ICAD (Intracranial Atherosclerotic Disease) Pathology Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Argentina ICAD (Intracranial Atherosclerotic Disease) Pathology Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Argentina ICAD (Intracranial Atherosclerotic Disease) Pathology Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Chile ICAD (Intracranial Atherosclerotic Disease) Pathology Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Chile ICAD (Intracranial Atherosclerotic Disease) Pathology Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Chile ICAD (Intracranial Atherosclerotic Disease) Pathology Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Colombia ICAD (Intracranial Atherosclerotic Disease) Pathology Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Colombia ICAD (Intracranial Atherosclerotic Disease) Pathology Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Colombia ICAD (Intracranial Atherosclerotic Disease) Pathology Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. Peru ICAD (Intracranial Atherosclerotic Disease) Pathology Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. Peru ICAD (Intracranial Atherosclerotic Disease) Pathology Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. Peru ICAD (Intracranial Atherosclerotic Disease) Pathology Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. Saudi Arabia ICAD (Intracranial Atherosclerotic Disease) Pathology Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. Saudi Arabia ICAD (Intracranial Atherosclerotic Disease) Pathology Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. Saudi Arabia ICAD (Intracranial Atherosclerotic Disease) Pathology Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Israel ICAD (Intracranial Atherosclerotic Disease) Pathology Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Israel Arabia ICAD (Intracranial Atherosclerotic Disease) Pathology Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Israel Arabia ICAD (Intracranial Atherosclerotic Disease) Pathology Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. UAE ICAD (Intracranial Atherosclerotic Disease) Pathology Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. UAE ICAD (Intracranial Atherosclerotic Disease) Pathology Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. UAE ICAD (Intracranial Atherosclerotic Disease) Pathology Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. Turkey ICAD (Intracranial Atherosclerotic Disease) Pathology Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 116. Turkey ICAD (Intracranial Atherosclerotic Disease) Pathology Sales Value Share by Type, 2025 VS 2032 & (%) Figure 117. Turkey ICAD (Intracranial Atherosclerotic Disease) Pathology Sales Value Share by Application, 2025 VS 2032 & (%) Figure 118. Iran ICAD (Intracranial Atherosclerotic Disease) Pathology Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 119. Iran ICAD (Intracranial Atherosclerotic Disease) Pathology Sales Value Share by Type, 2025 VS 2032 & (%) Figure 120. Iran ICAD (Intracranial Atherosclerotic Disease) Pathology Sales Value Share by Application, 2025 VS 2032 & (%) Figure 121. Egypt ICAD (Intracranial Atherosclerotic Disease) Pathology Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 122. Egypt ICAD (Intracranial Atherosclerotic Disease) Pathology Sales Value Share by Type, 2025 VS 2032 & (%) Figure 123. Egypt ICAD (Intracranial Atherosclerotic Disease) Pathology Sales Value Share by Application, 2025 VS 2032 & (%) Figure 124. ICAD (Intracranial Atherosclerotic Disease) Pathology Value Chain Figure 125. Manufacturing Cost Structure Figure 126. ICAD (Intracranial Atherosclerotic Disease) Pathology Sales Mode & Process Figure 127. Direct Comparison with Distribution Share Figure 128. Distributors Profiles Figure 129. Years Considered Figure 130. Research Process Figure 131. Key Executives Interviewed

Scope & coverage.

Types
  • Stent
  • PTA Balloon
Applications
  • Hospital
  • Clinic
  • Other
Companies covered
  • Stryker
  • Balt
  • TERUMO
  • MicroPort
  • Acandis

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global ICAD (Intracranial Atherosclerotic Disease) Pathology Sales Value (2021-2032)
  4. 1.2.2 Global ICAD (Intracranial Atherosclerotic Disease) Pathology Sales Volume (2021-2032)
  5. 1.2.3 Global ICAD (Intracranial Atherosclerotic Disease) Pathology Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 ICAD (Intracranial Atherosclerotic Disease) Pathology Market Dynamics
  1. 2.1 ICAD (Intracranial Atherosclerotic Disease) Pathology Industry Trends
  2. 2.2 ICAD (Intracranial Atherosclerotic Disease) Pathology Industry Drivers
  3. 2.3 ICAD (Intracranial Atherosclerotic Disease) Pathology Industry Opportunities and Challenges
  4. 2.4 ICAD (Intracranial Atherosclerotic Disease) Pathology Industry Restraints
3 ICAD (Intracranial Atherosclerotic Disease) Pathology Market by Company
  1. 3.1 Global ICAD (Intracranial Atherosclerotic Disease) Pathology Company Revenue Ranking in 2025
  2. 3.2 Global ICAD (Intracranial Atherosclerotic Disease) Pathology Revenue by Company (2021-2026)
  3. 3.3 Global ICAD (Intracranial Atherosclerotic Disease) Pathology Sales Volume by Company (2021-2026)
  4. 3.4 Global ICAD (Intracranial Atherosclerotic Disease) Pathology Average Price by Company (2021-2026)
  5. 3.5 Global ICAD (Intracranial Atherosclerotic Disease) Pathology Company Ranking (2024-2026)
  6. 3.6 Global ICAD (Intracranial Atherosclerotic Disease) Pathology Company Manufacturing Base and Headquarters
  7. 3.7 Global ICAD (Intracranial Atherosclerotic Disease) Pathology Company Product Type and Application
  8. 3.8 Global ICAD (Intracranial Atherosclerotic Disease) Pathology Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global ICAD (Intracranial Atherosclerotic Disease) Pathology Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 ICAD (Intracranial Atherosclerotic Disease) Pathology Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 ICAD (Intracranial Atherosclerotic Disease) Pathology Market by Type
  1. 4.1 ICAD (Intracranial Atherosclerotic Disease) Pathology Type Introduction
  2. 4.1.1 Stent
  3. 4.1.2 PTA Balloon
  4. 4.2 Global ICAD (Intracranial Atherosclerotic Disease) Pathology Sales Volume by Type
  5. 4.2.1 Global ICAD (Intracranial Atherosclerotic Disease) Pathology Sales Volume by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global ICAD (Intracranial Atherosclerotic Disease) Pathology Sales Volume by Type (2021-2032)
  7. 4.2.3 Global ICAD (Intracranial Atherosclerotic Disease) Pathology Sales Volume Share by Type (2021-2032)
  8. 4.3 Global ICAD (Intracranial Atherosclerotic Disease) Pathology Sales Value by Type
  9. 4.3.1 Global ICAD (Intracranial Atherosclerotic Disease) Pathology Sales Value by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global ICAD (Intracranial Atherosclerotic Disease) Pathology Sales Value by Type (2021-2032)
  11. 4.3.3 Global ICAD (Intracranial Atherosclerotic Disease) Pathology Sales Value Share by Type (2021-2032)
5 ICAD (Intracranial Atherosclerotic Disease) Pathology Market by Application
  1. 5.1 ICAD (Intracranial Atherosclerotic Disease) Pathology Application Introduction
  2. 5.1.1 Hospital
  3. 5.1.2 Clinic
  4. 5.1.3 Other
  5. 5.2 Global ICAD (Intracranial Atherosclerotic Disease) Pathology Sales Volume by Application
  6. 5.2.1 Global ICAD (Intracranial Atherosclerotic Disease) Pathology Sales Volume by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global ICAD (Intracranial Atherosclerotic Disease) Pathology Sales Volume by Application (2021-2032)
  8. 5.2.3 Global ICAD (Intracranial Atherosclerotic Disease) Pathology Sales Volume Share by Application (2021-2032)
  9. 5.3 Global ICAD (Intracranial Atherosclerotic Disease) Pathology Sales Value by Application
  10. 5.3.1 Global ICAD (Intracranial Atherosclerotic Disease) Pathology Sales Value by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global ICAD (Intracranial Atherosclerotic Disease) Pathology Sales Value by Application (2021-2032)
  12. 5.3.3 Global ICAD (Intracranial Atherosclerotic Disease) Pathology Sales Value Share by Application (2021-2032)
6 ICAD (Intracranial Atherosclerotic Disease) Pathology Regional Sales and Value Analysis
  1. 6.1 Global ICAD (Intracranial Atherosclerotic Disease) Pathology Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global ICAD (Intracranial Atherosclerotic Disease) Pathology Sales by Region (2021-2032)
  3. 6.2.1 Global ICAD (Intracranial Atherosclerotic Disease) Pathology Sales by Region: 2021-2026
  4. 6.2.2 Global ICAD (Intracranial Atherosclerotic Disease) Pathology Sales by Region (2027-2032)
  5. 6.3 Global ICAD (Intracranial Atherosclerotic Disease) Pathology Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global ICAD (Intracranial Atherosclerotic Disease) Pathology Sales Value by Region (2021-2032)
  7. 6.4.1 Global ICAD (Intracranial Atherosclerotic Disease) Pathology Sales Value by Region: 2021-2026
  8. 6.4.2 Global ICAD (Intracranial Atherosclerotic Disease) Pathology Sales Value by Region (2027-2032)
  9. 6.5 Global ICAD (Intracranial Atherosclerotic Disease) Pathology Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America ICAD (Intracranial Atherosclerotic Disease) Pathology Sales Value (2021-2032)
  12. 6.6.2 North America ICAD (Intracranial Atherosclerotic Disease) Pathology Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe ICAD (Intracranial Atherosclerotic Disease) Pathology Sales Value (2021-2032)
  15. 6.7.2 Europe ICAD (Intracranial Atherosclerotic Disease) Pathology Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific ICAD (Intracranial Atherosclerotic Disease) Pathology Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific ICAD (Intracranial Atherosclerotic Disease) Pathology Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America ICAD (Intracranial Atherosclerotic Disease) Pathology Sales Value (2021-2032)
  21. 6.9.2 South America ICAD (Intracranial Atherosclerotic Disease) Pathology Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa ICAD (Intracranial Atherosclerotic Disease) Pathology Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa ICAD (Intracranial Atherosclerotic Disease) Pathology Sales Value Share by Country, 2025 VS 2032
7 ICAD (Intracranial Atherosclerotic Disease) Pathology Country-level Sales and Value Analysis
  1. 7.1 Global ICAD (Intracranial Atherosclerotic Disease) Pathology Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global ICAD (Intracranial Atherosclerotic Disease) Pathology Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global ICAD (Intracranial Atherosclerotic Disease) Pathology Sales by Country (2021-2032)
  4. 7.3.1 Global ICAD (Intracranial Atherosclerotic Disease) Pathology Sales by Country (2021-2026)
  5. 7.3.2 Global ICAD (Intracranial Atherosclerotic Disease) Pathology Sales by Country (2027-2032)
  6. 7.4 Global ICAD (Intracranial Atherosclerotic Disease) Pathology Sales Value by Country (2021-2032)
  7. 7.4.1 Global ICAD (Intracranial Atherosclerotic Disease) Pathology Sales Value by Country (2021-2026)
  8. 7.4.2 Global ICAD (Intracranial Atherosclerotic Disease) Pathology Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA ICAD (Intracranial Atherosclerotic Disease) Pathology Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA ICAD (Intracranial Atherosclerotic Disease) Pathology Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA ICAD (Intracranial Atherosclerotic Disease) Pathology Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada ICAD (Intracranial Atherosclerotic Disease) Pathology Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada ICAD (Intracranial Atherosclerotic Disease) Pathology Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada ICAD (Intracranial Atherosclerotic Disease) Pathology Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico ICAD (Intracranial Atherosclerotic Disease) Pathology Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico ICAD (Intracranial Atherosclerotic Disease) Pathology Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico ICAD (Intracranial Atherosclerotic Disease) Pathology Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany ICAD (Intracranial Atherosclerotic Disease) Pathology Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany ICAD (Intracranial Atherosclerotic Disease) Pathology Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany ICAD (Intracranial Atherosclerotic Disease) Pathology Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France ICAD (Intracranial Atherosclerotic Disease) Pathology Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France ICAD (Intracranial Atherosclerotic Disease) Pathology Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France ICAD (Intracranial Atherosclerotic Disease) Pathology Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. ICAD (Intracranial Atherosclerotic Disease) Pathology Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. ICAD (Intracranial Atherosclerotic Disease) Pathology Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. ICAD (Intracranial Atherosclerotic Disease) Pathology Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy ICAD (Intracranial Atherosclerotic Disease) Pathology Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy ICAD (Intracranial Atherosclerotic Disease) Pathology Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy ICAD (Intracranial Atherosclerotic Disease) Pathology Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain ICAD (Intracranial Atherosclerotic Disease) Pathology Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain ICAD (Intracranial Atherosclerotic Disease) Pathology Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain ICAD (Intracranial Atherosclerotic Disease) Pathology Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia ICAD (Intracranial Atherosclerotic Disease) Pathology Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia ICAD (Intracranial Atherosclerotic Disease) Pathology Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia ICAD (Intracranial Atherosclerotic Disease) Pathology Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands ICAD (Intracranial Atherosclerotic Disease) Pathology Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands ICAD (Intracranial Atherosclerotic Disease) Pathology Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands ICAD (Intracranial Atherosclerotic Disease) Pathology Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries ICAD (Intracranial Atherosclerotic Disease) Pathology Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries ICAD (Intracranial Atherosclerotic Disease) Pathology Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries ICAD (Intracranial Atherosclerotic Disease) Pathology Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China ICAD (Intracranial Atherosclerotic Disease) Pathology Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China ICAD (Intracranial Atherosclerotic Disease) Pathology Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China ICAD (Intracranial Atherosclerotic Disease) Pathology Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan ICAD (Intracranial Atherosclerotic Disease) Pathology Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan ICAD (Intracranial Atherosclerotic Disease) Pathology Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan ICAD (Intracranial Atherosclerotic Disease) Pathology Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea ICAD (Intracranial Atherosclerotic Disease) Pathology Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea ICAD (Intracranial Atherosclerotic Disease) Pathology Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea ICAD (Intracranial Atherosclerotic Disease) Pathology Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India ICAD (Intracranial Atherosclerotic Disease) Pathology Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India ICAD (Intracranial Atherosclerotic Disease) Pathology Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India ICAD (Intracranial Atherosclerotic Disease) Pathology Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia ICAD (Intracranial Atherosclerotic Disease) Pathology Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia ICAD (Intracranial Atherosclerotic Disease) Pathology Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia ICAD (Intracranial Atherosclerotic Disease) Pathology Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia ICAD (Intracranial Atherosclerotic Disease) Pathology Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia ICAD (Intracranial Atherosclerotic Disease) Pathology Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia ICAD (Intracranial Atherosclerotic Disease) Pathology Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil ICAD (Intracranial Atherosclerotic Disease) Pathology Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil ICAD (Intracranial Atherosclerotic Disease) Pathology Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil ICAD (Intracranial Atherosclerotic Disease) Pathology Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina ICAD (Intracranial Atherosclerotic Disease) Pathology Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina ICAD (Intracranial Atherosclerotic Disease) Pathology Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina ICAD (Intracranial Atherosclerotic Disease) Pathology Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile ICAD (Intracranial Atherosclerotic Disease) Pathology Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile ICAD (Intracranial Atherosclerotic Disease) Pathology Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile ICAD (Intracranial Atherosclerotic Disease) Pathology Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia ICAD (Intracranial Atherosclerotic Disease) Pathology Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia ICAD (Intracranial Atherosclerotic Disease) Pathology Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia ICAD (Intracranial Atherosclerotic Disease) Pathology Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru ICAD (Intracranial Atherosclerotic Disease) Pathology Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru ICAD (Intracranial Atherosclerotic Disease) Pathology Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru ICAD (Intracranial Atherosclerotic Disease) Pathology Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia ICAD (Intracranial Atherosclerotic Disease) Pathology Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia ICAD (Intracranial Atherosclerotic Disease) Pathology Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia ICAD (Intracranial Atherosclerotic Disease) Pathology Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel ICAD (Intracranial Atherosclerotic Disease) Pathology Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel ICAD (Intracranial Atherosclerotic Disease) Pathology Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel ICAD (Intracranial Atherosclerotic Disease) Pathology Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE ICAD (Intracranial Atherosclerotic Disease) Pathology Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE ICAD (Intracranial Atherosclerotic Disease) Pathology Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE ICAD (Intracranial Atherosclerotic Disease) Pathology Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey ICAD (Intracranial Atherosclerotic Disease) Pathology Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey ICAD (Intracranial Atherosclerotic Disease) Pathology Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey ICAD (Intracranial Atherosclerotic Disease) Pathology Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran ICAD (Intracranial Atherosclerotic Disease) Pathology Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran ICAD (Intracranial Atherosclerotic Disease) Pathology Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran ICAD (Intracranial Atherosclerotic Disease) Pathology Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt ICAD (Intracranial Atherosclerotic Disease) Pathology Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt ICAD (Intracranial Atherosclerotic Disease) Pathology Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt ICAD (Intracranial Atherosclerotic Disease) Pathology Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Stryker
  2. 8.1.1 Stryker Company Information
  3. 8.1.2 Stryker Business Overview
  4. 8.1.3 Stryker ICAD (Intracranial Atherosclerotic Disease) Pathology Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Stryker ICAD (Intracranial Atherosclerotic Disease) Pathology Product Portfolio
  6. 8.1.5 Stryker Recent Developments
  7. 8.2 Balt
  8. 8.2.1 Balt Company Information
  9. 8.2.2 Balt Business Overview
  10. 8.2.3 Balt ICAD (Intracranial Atherosclerotic Disease) Pathology Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Balt ICAD (Intracranial Atherosclerotic Disease) Pathology Product Portfolio
  12. 8.2.5 Balt Recent Developments
  13. 8.3 TERUMO
  14. 8.3.1 TERUMO Company Information
  15. 8.3.2 TERUMO Business Overview
  16. 8.3.3 TERUMO ICAD (Intracranial Atherosclerotic Disease) Pathology Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 TERUMO ICAD (Intracranial Atherosclerotic Disease) Pathology Product Portfolio
  18. 8.3.5 TERUMO Recent Developments
  19. 8.4 MicroPort
  20. 8.4.1 MicroPort Company Information
  21. 8.4.2 MicroPort Business Overview
  22. 8.4.3 MicroPort ICAD (Intracranial Atherosclerotic Disease) Pathology Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 MicroPort ICAD (Intracranial Atherosclerotic Disease) Pathology Product Portfolio
  24. 8.4.5 MicroPort Recent Developments
  25. 8.5 Acandis
  26. 8.5.1 Acandis Company Information
  27. 8.5.2 Acandis Business Overview
  28. 8.5.3 Acandis ICAD (Intracranial Atherosclerotic Disease) Pathology Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Acandis ICAD (Intracranial Atherosclerotic Disease) Pathology Product Portfolio
  30. 8.5.5 Acandis Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 ICAD (Intracranial Atherosclerotic Disease) Pathology Value Chain Analysis
  2. 9.1.1 ICAD (Intracranial Atherosclerotic Disease) Pathology Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 ICAD (Intracranial Atherosclerotic Disease) Pathology Sales Mode & Process
  6. 9.2 ICAD (Intracranial Atherosclerotic Disease) Pathology Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 ICAD (Intracranial Atherosclerotic Disease) Pathology Distributors
  9. 9.2.3 ICAD (Intracranial Atherosclerotic Disease) Pathology Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst